|Baxter Enrolls First Patients in U.S. and Colombia Clinical Trials for HDx Therapy Enabled by THERANOVA|
|View printer-friendly version|
Baxter’s HDx therapy enabled by THERANOVA was designed to remove large
molecular weight toxins that have been associated with inflammation and
cardiovascular health for end-stage renal disease (ESRD) patients.1,2,3
The dialyzer is available in select countries around the world including
“These clinical trials allow us to examine the effectiveness and safety
of THERANOVA and assess patient relevant outcomes, including
health-related quality of life measures and dialysis symptoms,” said
Hemodialysis (HD) therapy is used to treat nearly three million ESRD patients worldwide, and is most often performed three times a week in a clinic. The therapy works by cleaning the blood of toxins and removing extra fluids when it is pumped through an artificial kidney filter or dialyzer, such as THERANOVA.
HDx therapy extends the range of molecules that can be cleared from the blood during HD, resulting in a clearance profile that more closely mimics the natural kidney.4 HDx therapy enabled by THERANOVA is performed during conventional HD therapy, does not require generation of replacement fluid and works on standard equipment for operational efficiencies.
In a previous study published in Nephrology Dialysis Transplantation, researchers found that HDx enabled by the THERANOVA dialyzer can exceed the performance of other types of dialysis, including high flux hemodialysis and high-volume hemodiafiltration (HDF) for specific large middle molecules, with acceptable albumin removal.5 Additionally, independent data presented at ERA-EDTA 2017 indicated HDx therapy effectively removed small and mid-sized toxins at similar rates when compared to high-volume HDF using a larger hemofilter.6
“Millions of patients with chronic kidney disease rely on renal
innovations every day, many of whom have ESRD and require HD therapy to
stay alive,” said
HDx enabled by THERANOVA is available in
For prescription only. For safe and proper use of the devices mentioned herein, refer to the THERANOVA Instructions for Use.
Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
This release includes forward-looking statements concerning HDx
enabled by THERANOVA, one of Baxter’s dialysis membranes, including
expectations regarding its potential impact on patients and anticipated
benefits associated with its use. The statements are based on
assumptions about many important factors, including the following, which
could cause actual results to differ materially from those in the
forward-looking statements: satisfaction of regulatory and other
requirements; actions of regulatory bodies and other governmental
authorities; product quality, manufacturing or supply, or patient safety
issues; changes in law and regulations; and other risks identified in
Baxter's most recent filing on Form 10-K and other
Baxter and THERANOVA are registered trademarks of
Baxter International Inc.